Dupuis J et al. Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): An open-label randomised, phase 3 study. Lancet Haematol 2024;11(6):e406-14. Abstract

Dupuis J et al. Oral azacytidine in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma: Final analysis of the oracle phase III study. ASH 2022;Abstract 624.

Herrera AF et al. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 study. Lancet Haematol 2024;11(9):e671-81. Abstract

Horwitz S et al. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma. Ann Oncol 2022;33(3):288-98. Abstract

Savage KJ et al. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv 2022;6(19):5550-5. Abstract

Zinzani PL et al. Zanubrutinib + obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Primary analysis of the phase 2 randomized rosewood trial. EHA 2022;Abstract S205.